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Abstract
Background: Despite favourable results from past meta-analyses, some recent large trials have not found Heart
Failure (HF) disease management programs to be beneficial. To explore reasons for this, we evaluated evidence
from existing meta-analyses.
Methods: Systematic review incorporating meta-review was used. We selected meta-analyses of randomized
controlled trials published after 1995 in English that examined the effects of HF disease management programs on
key outcomes. Databases searched: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR), DARE,
NHS EED, NHS HTA, Ageline, AMED, Scopus, Web of Science and CINAHL; cited references, experts and existing
reviews were also searched.
Results: 15 meta-analyses were identified containing a mean of 18.5 randomized trials of HF interventions +/- 10.1
(range: 6 to 36). Overall quality of the meta-analyses was very mixed (Mean AMSTAR Score = 6.4 +/- 1.9; range 2-9).
Reporting inadequacies were widespread around populations, intervention components, settings and
characteristics, comparison, and comparator groups. Heterogeneity (statistical, clinical, and methodological) was not
taken into account sufficiently when drawing conclusions from pooled analyses.
Conclusions: Meta-analyses of heart failure disease management programs have promising findings but often fail
to report key characteristics of populations, interventions, and comparisons. Existing reviews are of mixed quality
and do not adequately take account of program complexity and heterogeneity.
Background
Heart failure (HF) disease management programs are
common in North America, Europe, and Australia [1,2].
These services provide care to optimize pharmacological
regimen and support medication management and effec-
tive self-care. Programs have been widely introduced fol-
lowing recommendations from international clinical
guidelines [1,3,4] but a number of recent and compara-
tively large trials have found no or small benefits from
programs [5-10]. These inconsistencies have been
explained by design issues rather than biases, reporting
inadequacies or differences in actual effects [11,12].
However, recent results from the United States of the
Medicare Health Support Pilot Program (MHSPP) [13]
provide corroboration that program effects are poorly
understood. This independent randomized trial of nine
disease management programs with 30,000 patients with
heart failure and diabetes concluded that programs did
not decrease mortality, frequency of hospitalization,
costs, or improve self-care, self-care efficacy, or mental
and physical health [13].
T h e s er e s u l t sr a i s eq u e s t ions about what clinicians
should do in the light of contradictory evidence from
trials and meta-analyses. When results from trials differ,
it should not be concluded that an intervention is inef-
fective because most trials are underpowered to identify
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of power but are as prone to reporting and design flaws
as any other type of research design [15]. Though find-
ings from meta-analyses frequently influence guidelines,
like any other research design, as the recent PRISMA
guidelines acknowledge, systematic reviews can vary
widely in quality [16,17].
Thus, the methods and overall quality of meta-analysis
are of great importance. Despite this, there has been no
systematic appraisal of the quality of meta-analyses of
heart failure management programs to date. This is par-
ticularly important given the increasing awareness of the
complexity and diversity of these programs [18]. To
evaluate the strength of evidence from current meta-
analyses of these programs, we appraised the nature and
quality of evidence from existing published meta-ana-
lyses of HF disease management programs.
Methods
Meta-review was used to identify and appraise evidence
from published meta-analyses of heart failure disease
management programs or approaches. Meta-review
appraises and synthesises findings from systematic
reviews, in this instance, from meta-analyses [19]. The
approach has evolved in response to the growing num-
ber of systematic reviews and the need to appraise qual-
ity of a review before application to practice and policy,
for example via PRISMA [17].
Meta-review follows similar principles to systematic
review [19]: it involves a comprehensive and detailed
search of the literature for relevant studies with quality
assessment to assess for bias, transparency, and compre-
hensiveness [19]. As with traditional systematic review, in
meta-review, validation of quality by a second, independent
reviewer is important to reduce potential for bias [19].
A comprehensive search was done to identify meta-
analyses of randomized controlled trials published in
English that examined the effects of HF disease manage-
ment programs on key outcomes. To be included,
reviews had to have a detailed and comprehensive
search strategy (as identified by: naming of databases
and years of searching and example or actual terms),
contain data on study quality and make reference to
synthesis of findings either by pooling data or rejecting
the pooling of data. Due to changes in clinical practice,
and to ensure some degree of congruence with contem-
porary clinical practice, we searched only for meta-ana-
lyses published after 1995, confined our search to
reviews that contained comparisons of programs with
usual care, and included samples of adults over the age
of 18 years with confirmed diagnosis of HF. Meta-ana-
lyses of interventions that included patients with other
forms of cardiac disease (such as cardiac rehabilitation
or secondary prevention) that may have addressed heart
failure disease management were not included due to
the lack of data specific to heart failure populations in
these reviews [20,21]. Finally, the meta-analyses had to
contain extractable data for HF patients on mortality
(all-cause or HF related), hospital (re)admission (all-
cause and HF related),o rhealth-related quality of life.
For the purposes of the review, interventions were
defined as HF management programs if they consisted
of more than one recognized disease management com-
ponent (medication optimization, lifestyle modification,
or education) with the purpose of improving outcomes
related to HF in patients with a confirmed diagnosis or
were self-identified by the authors as constituting a pro-
gram or analogous health service intervention beyond
usual care for the treatment of HF.
A variety of electronic databases using a range of
search terms (Table 1) were searched, including: MED-
LINE, EMBASE, Cochrane Database of Systematic
Reviews (CDSR), DARE, NHS EED, NHS HTA, Ageline,
AMED, Scopus, Web of Science and CINAHL from 1
st
January 1995 to July 31, 2008. In addition, reference lists
and bibliographies of identified reviews were hand
searched.
The primary screening was conducted independently
by LS and AMC with abstracts/titles being screened
fully. Full papers for potential inclusion were then
screened by LS and AMC for detailed evaluation with
disagreements regarding eligibility being handled with
joint discussion between LS, AMC, and DRT.
Data were extracted onto a standardized data extrac-
tion template relating to: population, intervention, com-
parison, and outcome (PICO). This approach has been
developed for optimizing evidence-based practice. Qual-
ity of each meta-analysis was assessed independently by
LS and AMC using a standardized and valid measure of
quality of systematic review (AMSTAR) [22].
Results
4529 potential articles were initially identified (Figure 1)
but primary screening excluded 4285 papers. After
reviewing the remaining papers (n = 244), 15 meta-ana-
lyses met the inclusion criteria (Table 2).
Table 1 Search terms used
Disease management-related Heart failure-
related
Disease management program (exp),
manag(exp), educat(exp),
Chronic disease (exp), program(exp), coach, usual
care, counsel(exp), directive, organization, managed
care programs, patient education, disease
management (exp), care management (exp),
randomized trial, program evaluation, evaluat(exp),
meta-anal(exp), metaanal(exp), review(exp)
Heart failure
(exp)
chf
Exp: Exploded search
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Manually reviewed (full papers) 
against inclusion criteria
105 papers rejected
Excluded after detailed reviewing of study as:
not English
not published between 1995-2008
duplicate study
not a meta-analysis
15 papers
Studies included for detailed review
4529 papers
Relevant studies identified 
electronically throughsystematic 
search of databases
4285 papers rejected
Excluded based on screening of title/abstract as not a 
systematic review ofinterventions for HF
244 papers
Screened for detailed evaluation
124 papers rejected
Excluded after reviewing of abstract /study as:
not a disease management program for 
HF
HF not extractable
not a systematic review
single modality intervention
Figure 1 Results of the systematic search strategy and study selection process.
Table 2 Meta-analyses included in review
Review (Reference
number)
Number of trials N of total
sample
Sex
(% males)
Mean Age SD
Age
Age Range
(Years)
AMSTAR
Score
Koshman et al. [35] 12 2060 NR NR NR 58-80 7
Clark et al. [25] 14 4264 NR NR NR 57-75 8
Gohler et al. [32] 36 8341 37-99% NR NR 56-79 5
Jovicic et al. [24] 6 857 53-76% NR NR 56-76 7
Holland et al. [34] 30 NR 27-99% NR NR 56-80 4
Kim & Soeken [23] 4 NR NR NR NR NR to 64.0 to
81.6
6
Phillips et al. [31] 6 949 58% 73 NR 62-79 8
Roccaforte et al. [28] 33 3817 42% 73 NR NR 8
Taylor et al. [27] 16 1627 23-86% NR NR 70-80 9
Whellan et al. [36] 19 5752 NR NR NR 56-80 2
Gonseth et al. [37] 54: 27 randomized and 27 non-
randomized
3160 NR Over 70 in most
trials
NR Not
summarized
9
Gwadry-Sridhar et al.
[33]
8 1239 37-58% NR NR 71 -80.3 6
McAlister et al. [30] 29 5039 NR NR NR 56-80 5
Phillips et al. [29] 18 3304 62% NR NR NR 7
McAlister et al. [26] 11 2067 NR NR NR 63-80 5
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18.5 randomized trials +/- 10.1 (range: 6 to 36) and a
mean of 3267.4 patients +/- 2184.0. Two reviews did
n o tr e p o r ts a m p l es i z e[ 9 , 2 3 ] .O v e r a l lq u a l i t yo ft h e
meta-analyses based on AMSTAR criteria [22] was
moderate but varied widely (Mean Score = 6.4 +/- 1.9;
range 2-9). Main weaknesses in the reviews were lack of
incorporation of study quality in conclusions and low
detail regarding excluded studies (Additional file 1).
Search Strategies
Most reviews searched for published and unpublished
trials [9,24-31]; four identified that grey literature was
searched [9,26,27,30]. Though only one review limited
its search to English-only papers, [32] the overall quality
of search strategies was moderate: three reviews
described a full Boolean strategy [24,27,33] and eight
provided a QUOROM-like flow chart [25,28-31,33-35].
Most reviews included an assessment of publication bias
via a funnel plot [23-25,28,29,31,32,34].
Populations
Mean age of the review population was calculated in
two reviews [28,31] (both mean age: 73 years) with the
oldest reported mean age being 81.6 [23]. Seven reviews
[23,26,27,30,33,34,36] reported an upper age limit of 80
years. The lowest mean age reported was 56 by five
reviews by way of inclusion of the same trial
[24,30,32,34,36]. Two additional reviews reported lower
mean age limits of 57 and 58 [25,35] but none presented
data on standard deviation of ages.
Six reviews [23,25,26,30,35,36] provided no data on
the sex of the participants in the trials. Co-morbidities
and characteristics of study populations were frequently
not reported with particular weaknesses in reporting of
medication treatments (Table 3). Of the four studies
that did report co-morbidities, [26,31,36,37] hyperten-
sion, diabetes, chronic obstructive lung disease, and cor-
onary artery disease were most common.
Interventions
Definitions of trials
Reviews most frequently used operationalised definitions
(Table 4) to guide inclusion of interventions, though
only three used definitions involving approach, person-
nel, setting, and content [23,26,27]. The foci of reviews
differed markedly, for example, reviews specified inter-
ventions provided only in particular settings, [23,25-27]
or without reference at all to content [25,34,37].
Interventions included
Interventions included in reviews mostly spanned three to
five patient settings or modes of provision; only two were
focused on interventions using single or comparable set-
tings or mode of provision [23,25]. Interventions included
in reviews were wide ranging (Table 4) in terms of number
and type of settings and locations. For example, nine
reviews included programs with both hospital and home-
based components [27-29,31,33-37] and two reviews
included studies that employed interventions in all settings
[29,34]. Nurses were the most frequent providers of care
through ‘multi-disciplinary team’ interventions. Additional
physician involvement via cardiologist or general practi-
tioner was identified in nine reviews [26,28-32,35-37]
though three reviews involved both general practitioners
and cardiologists [26,30,36]. All reviews but one [24] iden-
tified other personnel involved, for example: pharmacist or
pharmacist collaboration [28-30,32,35,37].
Program Content
The reviews specified a mean of 1.13 essential compo-
nents of content (range 0 to 3). Interventions were
described in terms of content using general descriptors,
such as education, self-care, discharge plan, and medica-
tion support. Reviews most commonly stated that inter-
ventions had to have three or four component items
though reviews could extend to five or more content
components [26,30,37]. Educational and monitoring
interventions were the most commonly identified ele-
ments. Other components included support at hospital
discharge, medication review, and social support. Hence,
Table 3 Select population characteristics
Reporting of population characteristics
No information on co-morbidities 7/15 [24,25,29,30,32,33,35]
Incomplete or no data on NYHA Classification 10/15 [9,23,24,26,27,29,30,33,35-37]
No data on NYHA Classification 4/15 [23,26,27,30]
Range of NYHA Classification only 6/15 [24,25,28,31,32,37]
Information on LVEF 6/15 [25,29,31,34,36,37]
Summaries of ACE-I and BB medication treatments 3/15 [32,36,37]
aNYHA, New York Heart Association
bLVEF, Left Ventricular Ejection Fraction
cACE-I, Ace-Inhibitor
dBB, Beta Blocker
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a systematic review may focus on a nurse-led hospital-
based intervention yet offers home visits, telephone sup-
port, and follow-up with a general practitioner [23].
Obtaining data on usual care was noted to be proble-
matic [23,27-29,32,35] and the care provided to compar-
ison groups was poorly defined (Table 5). For example,
in seven of twelve trials in one review, descriptions of
care were omitted entirely [35].
Outcomes
The follow-up period was 3 to 12 months in six reviews
[24,27,29,31,33,36]. Three studies reported beginning
follow-up periods at three months but the upper limit
extended to 16, 18, and 22 months [25,32,28]. Other
reviews did not report length of follow-up [34] or did
not report follow-up periods [23].
Within review pooling of outcomes
The meta-analyses pooled data on: all-cause mortality as
primary and secondary outcomes. (Table 6) Other
outcomes pooled included all-cause (re)admission, HF
mortality, HF (re)admission, quality of life, and cost.
Data were pooled using random [25,28,30,32-35] and
fixed effect models of analysis [24,27] or both methods
[26,29,31,37] if significant statistical heterogeneity was
identified.
Table 4 Definitions of trials and characteristics of interventions actually included
Definitions of interventions included in reviews
No definition 1/15 [33]
Operationalized definition 11/15 [23-27,30-32,34,36,37]
Definitions incorporate approach, personnel, setting and content 3/15 [23,26,27]
Concept of a disease management program 5/15 [26,28,30,31,36]
Concept of comprehensive treatment approach 6/15 [23,24,27,29,34,37]
Interventions provided in particular settings 4/15 [23,25-27]
Intervention Settings
Five settings/modes of provision 2/15 [29,34]
Four settings 7/15 [27,30,31,33,35-37]
Three settings 4/15 [24,26,28,32]
Single or comparable setting 2/15 [23,25]
Type of setting
All settings 2/15 [29,34]
Hospital (Pre-discharge) 10/15 [23,27-29,31,33-37]
Hospital and home-based components 9/15 [27-29,31,33-37]
Home and community 9/15 [27-29,31,33-37]
At home 13/15 [24,26-37]
Out-patient 13/15 [24,26-37]
Telephone 11/15 [24,25,27,29-35,37]
Remote provision 5/15 [25,29,30,34,36]
Professionals
Nurse-led 11/15 [23,24,26,28-32,34,36,37]
’Multi-disciplinary teams’ 10/15 [23,25,26,28,30,32-35,37]
Physician involvement via cardiologist or GP 9/15 [26,28-32,35-37]
Both cardiologist and GP 3/15 [26,30,36]
Pharmacist 6/15 [28-30,32,35,37]
Table 5 Components of interventions included and trial
quality
Number of components
3-4 8/15 [23,24,27-29,31,32,35]
> 4 3/15 [26,30,37]
Educational components 13/15 [23,24,26-35,37]
Monitoring via home visits or phone 13/15 [23,24,26-32,34-37]
Support at hospital discharge 10/15 [23,24,26,28-32,36,37]
Medication review 9/15 [24,26-28,30-32,35,37]
Social support 5/15 [26,27,29,30,37]
Comparison Groups
No information 11/15 [23-26,29-31,33,34,36,37]
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improvements in all cause mortality [25,28,30,32,34,37]
though all 13 reviews identified trends favouring pro-
grams over control. Effect sizes varied from 3% to 25%
but were mostly clustered around 15% to 20%. Larger
benefits were more evident in terms of hospitalisations.
All 9 reviews that measured changes in HF-related hos-
pitalizations [24,25,27-30,34,35,37] identified significant
reductions in admissions with reductions in risk ranging
from 30% to 56%. Out of 13 reviews, 10 reviews
[24,26,28-30,32-35,37] identified reductions in all-cause
readmission with reductions in risk ranging from 8% to
41% with most clustered around 15% to 25% reductions
in admission. Seven reviews extracted data on quality of
life or health-related quality of life [27-31,33,35]. (Table
7 )T h em a j o r i t yd i dn o tp o o lo u t c o m e sd u et oh i g h
levels of heterogeneity [27,28,33,35] or lack of data [30].
However, two reviews identified insignificant trends
favouring quality of life improvements after pooling
[29,31].
Due to the limited reporting of interventions and con-
trol groups and the diversity of trials included in the
reviews, it is not appropriate to pool outcomes from the
meta-analyses here. This is important because findings
from interventions that are excessively heterogeneous
should not be pooled. Particularly, this was the case
with these meta-analyses that varied and/or contained
unclear data pertaining to a wide range of factors and
strata of programs, for example, relating to clinical
populations, providers, location, mode of delivery, num-
bers of components, and length. These multiple ambigu-
ities made pooling, sensitivity analysis, and meta-
regression inappropriate [38-40].
Handling of uncertainty in the reporting of review results
Trial quality was inconsistently taken into account when
formulating conclusions and was not addressed in most
reviews. Statistical heterogeneity was discussed in most
reviews though clinical and methodological heterogene-
ity was consistently neglected (Table 8). Sensitivity ana-
lyses were carried out around a diverse range of
elements, including study quality, [23,28-30,34,35,37]
size, [37] and publication status [34]. Intervention-type,
[26,28] follow up, [26,30] diagnoses, [23] and elements
of interventions related to: components, [23,26] com-
plexity, [31] and provider-type [28,37]. Three reviews
selected factors a priori for sensitivity analysis
[26,30,37]. Sub-analyses were undertaken around ‘gen-
eral’ program features, [32] setting, [26,30,34] home-visit
or telephone contact, [26] and discharge planning
[29,31].
Discussion
This meta-review is the first of meta-analyses of HF dis-
ease management programs and conveys the challenges
of performing meta-analyses of complex health services
interventions. Overall, quality of the reviews was moder-
ate though very mixed across reviews - this quality is
important to consider when deciding whether review
findings should guide practice and guidelines [22,41,42].
Based on the consistency and size of effect sizes iden-
tified by the meta-analyses, it would immediately appear
reasonable to conclude either that, in generality, pro-
grams work or that programs of various types work
[43]. However, this meta-review supports concerns that
populations, programs, and analyses of these programs
are inconsistently and poorly described [44,45]. For
Table 6 Effect sizes of primary outcomes of reviews (95% Confidence Intervals)
Review (reference number) All cause mortality All cause re-hospitalization HF-related hospitalization
Koshman et al. [35] OR 0.84 (0.61-1.15) OR 0.71 (0.54-0.94) OR 0.69 (0.51-0.94)
Clark et al. [25] RR 0.80 (0.69-0.92) RR 0.95 (0.89-1.02) RR 0.79 (0.69-0.89)
Gohler et al. [32] RD 0.03 (0.01-0.05) RD 0.08 (0.05-0.11) NA
Jovicic et al. [24] OR 0.93 (0.57-1.51) OR 0.59 (0.44-0.80) OR 0.44 (0.27-0.71)
Holland et al. [34] RR 0.79 (0.69-0.92) RR 0.84 (0.79-0.95) RR 0.70 (0.61-0.81)
Kim & Soeken [23] NA OR 0.87 (0.69-1.04) NA
Phillips et al. [31] RR 0.80 (0.57-1.13) RR 0.91 (0.72-1.16) NA
Roccaforte et al. [28] OR 0.80 (0.69-0.93) OR 0.76 (0.69-0.94) OR 0.58 (0.50-0.67)
Taylor et al. [27] OR 0.86 (0.67-1.10) NA OR 0.52 (0.39-0.70)
Whellan et al. [36] NA NA NA
Gonseth et al. [37] RR 0.75 (0.59-0.96) RR 0.88 (0.79-0.97) RR 0.70 (0.62-0.79)
Gwadry-Sridhar et al. [33] RR 0.98 (0.72-1.34) RR 0.79 (0.68-0.91) NA
McAlister et al. [30] RR 0.83 (0.70-0.99) RR 0.84 (0.75-0.93) RR 0.73 (0.66-0.82)
Phillips et al. [29] RR 0.87(0.73-1.03) RR 0.75 (0.64-0.88) RR 0.65 (0.54-0.79)
McAlister et al. [26] RR 0.94 (0.75-1.19) RR 0.87 (0.79-0.96) NA
RR: Risk Ratio; RD: Risk Difference; OR: Odds Ratio
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populations and treatments with only one-fifth of
reviews defining programs comprehensively in terms of
approach, personnel, setting, and content. Even with the
use of operationalised definitions to guide study selec-
tion in reviews, findings from interventions with very
diverse characteristics and populations were pooled and,
though mentioned in reviews, the implications of trial
quality or statistical, clinical or methodological heteroge-
neity were seldom actually taken into account in ana-
lyses. No progress over time was evident in quality of
reporting. Hence, reviews continue to focus on the
results of study pooling over issues related to program
complexity and heterogeneity.
Why might program complexity and heterogeneity be
comparatively neglected in comparison to the findings
of reviews? Firstly, this emphasis is understandable due
to limitations in methodology. Complex interventions
are often poorly described in published manuscripts [46]
and it is well known that HF disease management pro-
grams are complex and diverse [43,45,47]. Current sta-
tistical and methodological techniques to describe and
analyse such interventions in systematic review remain
rudimentary [48]. Current meta-analyses also predate
the existence of a taxonomy to classify HF disease man-
agement programs [18] and more extensive CONSORT
reporting requirements for non-pharmacological trials
[49].
Secondly, scientific findings that are more positive are
more likely to be published in higher impact journals
Table 7 Direction of effects Quality of Life
Review Measures Pooling (Y/N) Result of pooling
Phillips et al. (2005)
[31]
NHP
MLHF
HFSBS
Y
(5/6 studies reported QOL)
+
Intervention: 30.6 ± 20.7% VS. control: 19.3 ± 12.6%,
p = 0.13
Gwadry-Sridhar et al.
(2004) [33]
SF-36 N
(4/8 studies reported HRQOL; precluded pooling)
RNPH
Koshman et al.
(2008) [35]
MLHF
COOP/WONCA
SF-36
EQ-5D
CHFQ
N
(7/12 studies reported HRQOL; precluded pooling)
RNPH
Roccaforte et al.
(2005) [28]
MLHF
SF-36
N
(16/33 studies reported QOL; varying presentation
of results precluded pooling)
RNPH
Taylor et al. (2005)
[27]
MLHF
QLHFQ
CHFQ
Time trade off
method (?)
N
(8/16 studies reported HRQOL; varying results)
RNPH
Phillips et al. (2004)
[29]
MLHF
NHP
HFSBS
SF-36
Y
(5/18 studies reported HRQOL)
+
Intervention: 25.7% [95% CI, 11.0%-40.4%] VS. control:
13.5% [95% CI, 5.1%-22.0%]
McAlister et al.
(2001) [26]
NR N (5/11 studies reported HRQOL) Insufficient data
HRQOL = Health-related quality of life; QOL = Quality of life
MLHF = Minnesota Living with Heart Failure Questionnaire; COOP/WONCA = Dartmouth Primary Care Cooperative Research Network/World Organization of
National Colleges, Academics and Academic Associations of General Practitioners/Family Physicians; SF-36 = 36-Item Short-Form Health Survey; EQ-5D = EuroQol-
5 Dimensions form
NHP = Nottingham Health Profile; HFSBS = Heart Failure Self Care Behaviour Scale; QLHFQ = Quality of Life in Heart Failure Questionnaire; CHFQ = Chronic Heart
Failure Questionnaire
RNPH: Results not pooled due to heterogeneity
+ = Non-significant trend favoring intervention
++ = Significant trend favoring intervention
Table 8 Trial quality and heterogeneity
Conclusions
Quality
Trial quality taken into account [35,37]
Trial quality mentioned [23,24,27,33]
Heterogeneity
Discussed [27,28,30,32,34,35,37]
Statistical Assessment [23-35,37]
Cochran’s Q test and I
2 statistic [23-35,37]
Clinical acknowledged [24,25,32]
Methodological acknowledged [26,33,35]
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incentives to qualify results to take account of ‘messy’
issues related to program diversity and heterogeneity
and fosters a disproportionate emphasis on positive
findings without qualification [52] or recognition of how
elements of context may moderate intervention effects
[53]. This tendency may be combined with a wider per-
ceived political need to champion multi-disciplinary
health services interventions to attain greater recogni-
tion and usage of such interventions in healthcare sys-
tems seen to favour pharmacological interventions and
biomedicine [54].
However, paradoxically, ignoring complexity and het-
erogeneity may actually reduce knowledge translation.
This follows because uptake is likely to be reduced by
unclear descriptions of what programs and comparison
groups consist of, lack of clarity over likely benefits in
important patient groups (for example: the effects of
both age and sex on program outcomes are not known),
and lack of specificity in findings regarding key program
characteristics [16,53].
In future reviews, programs should be described com-
prehensively using systematic classification methods
[18]. More sophisticated taxonomies are needed to fully
capture the deeper characteristics of programs [48].
T h e s es h o u l db eu s e di nf u t u r er e v i e w st od e s c r i b ep r o -
grams comprehensively and the effects of clinical, meth-
odological, and statistical heterogeneity - as per
PRISMA guidelines - must be formally taken into
account in methods and conclusions [15]. Future trials
should report key elements of populations, interven-
tions, comparison group, and outcomes in accordance
with the modified CONSORT statement for non-phar-
macological trials [49]. These factors should be incorpo-
rated and reported comprehensively in meta-analyses.
Findings from meta-analyses should be evaluated prior
to application to practice and policy with review quality
being assessed using valid quality criteria [15].
In terms of limitations, as with any review, this meta-
review was constrained by the quality of reporting of
the component studies. The data presented here are
descriptive because it was inappropriate to synthesise
outcomes to generate pooled effect sizes due to the
wide diversity of programs subsumed in the reviews and
the lack of comprehensive reporting in the reviews of
intervention, comparator groups, and population charac-
teristics [55,56]. As pivotal elements of programs,
reporting of these components has to be clear and com-
prehensive if synthesis is to be undertaken.
Conclusions
Meta-analyses of heart failure disease management pro-
grams have promising findings but often fail to report
key characteristics of populations, interventions, and
comparisons. Existing reviews are of mixed quality and
do not adequately take account of program complexity
and heterogeneity.
Additional material
Additional file 1: AMSTAR Quality Ranking of Included Studies.
Quality assessment ratings for each item on the AMSTAR tool for each
review.
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